Biotech | February 28, 2026
Synthekine teams up with Merck to test breakthrough lung cancer combo
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
The new patents cover critical advancements in cochlear implant technology
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Subscribe To Our Newsletter & Stay Updated
